Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States — Food and Drug Administration & United States — Medicare

8 shared events · Importance 3 · Last updated Sep 24, 2026

Importance
3
Shared Events
8
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
64
Regulatory
United States — Food and Drug Administration: Its advisory panel endorsed the test, but the agency still must make the final approval decision and has flagged efficacy concerns.
United States — Medicare: Legislation authorizes Medicare coverage of FDA-approved multi-cancer tests beginning in 2028, a key financial incentive for Grail.
Sep 23, 2026 · 18 articles
55
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration has granted Orphan Drug Designation to G2B-002 for DIPG and pGBM, which is a positive regulatory status for the drug's development.
United States — Medicare: United States — Medicare, through its subsidiary Shilpa Biocare Private Limited, has entered a strategic equity partnership with Gate2Brain, becoming a strategic shareholder and a key partner for manufacturing and regulatory aspects of G2B-002. This reinforces its commitment to innovation and long-term value creation.
Jun 08, 2026 · 7 articles
46
Domestic
United States — Food and Drug Administration: Approved updated flu and COVID-19 vaccines, including Moderna's mFlusiva, enabling their availability for the fall season.
United States — Medicare: Covers fall shots, facilitating access for beneficiaries and supporting vaccine uptake.
Sep 02, 2026 · 20 articles
30
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration has cleared the CareMiBrain system for use and has approved new monoclonal antibody treatments for Alzheimer's Disease, creating a market for the PET scans.
United States — Medicare: United States — Medicare covers brain PET scans for beta-amyloid plaque detection and new monoclonal antibody treatments for Alzheimer's Disease, which is crucial for patient access to Grey Matters Health Inc.'s services.
Jul 06, 2026 · 6 articles
20
Business
United States — Food and Drug Administration: Approved the tirzepatide label expansion into cardiovascular risk on August 28, 2026, and its pending review of retatrutide is a key 2027 catalyst for Lilly.
United States — Medicare: Its GLP-1 Bridge Program granted 20 million eligible Americans coverage at $50 per month, a volume tailwind cited in the Lilly bull case.
Sep 14, 2026 · 6 articles
0
Business
Jan 05, 2026 · 7 articles
0
Regulatory
Dec 18, 2025 · 15 articles
0
Regulatory
Dec 18, 2025 · 9 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States — Food and Drug Administration and United States — Medicare interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.